Floatz logo

(18F)FPPRGD2

Recurrent Basal Cell Carcinoma of the Lip

Sanjiv Sam Gambhirprotein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Recurrent Basal Cell Carcinoma of the Lip cohort.

Asset / SponsorPhaseRating
Irinotecan
Genentech, Inc.
Phase 2BB
Multiple Vitamins Injection
Women's College Hospital
Phase 3BB
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Gdc-0449
Genentech, Inc.
Phase 2B
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC

View all 32 →

Same molecule, other indications

(18F)FPPRGD2 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
gliosarcomaDormant
CCC
Indicative ·
52 / 100
View asset →
adult glioblastomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →